Loomis Sayles & Co. L P lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 707,222 shares of the biopharmaceutical company's stock after buying an additional 46,964 shares during the quarter. Loomis Sayles & Co. L P owned approximately 0.93% of Xenon Pharmaceuticals worth $27,843,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 641 shares during the last quarter. nVerses Capital LLC purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $102,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after buying an additional 487 shares during the last quarter. Quarry LP boosted its position in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $156,000 after acquiring an additional 2,700 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 12.0% during the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company's stock worth $228,000 after acquiring an additional 565 shares in the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
XENE has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Royal Bank of Canada reiterated an "outperform" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Wedbush dropped their price target on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $57.45.
Get Our Latest Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Performance
XENE traded up $0.77 on Tuesday, hitting $42.45. 454,889 shares of the company were exchanged, compared to its average volume of 389,770. Xenon Pharmaceuticals Inc. has a fifty-two week low of $29.00 and a fifty-two week high of $50.99. The firm has a market capitalization of $3.24 billion, a P/E ratio of -15.05 and a beta of 1.25. The business's fifty day moving average is $41.31 and its 200 day moving average is $40.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same period last year, the firm posted ($0.73) earnings per share. Analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.
Insider Activity
In related news, Director Gary Patou sold 4,891 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the sale, the director now owns 23,573 shares of the company's stock, valued at approximately $968,378.84. This represents a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.52% of the company's stock.
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
